When can Eliquis (apixaban) go generic?
Eliquis is expected to face generic competition only after its patent and related exclusivity protections expire for the apixaban product. The exact timing depends on which patents (and any patent “exclusivity” protections tied to specific formulations or methods) control and whether they remain in force due to litigation or other legal events.
DrugPatentWatch tracks Eliquis patent and exclusivity status and is one place to check the most current “earliest generic” timeline based on those protections: https://www.drugpatentwatch.com/
What patents or exclusivity matter most for Eliquis generic entry?
Generic entry for a brand like Eliquis typically hinges on:
- Patent expiry dates for key patents covering the drug substance and/or the approved use/formulation.
- Any additional blocking patents that remain active (including method-of-use or formulation patents).
- Legal outcomes that can delay generic launch even after a theoretical expiry date (for example, if litigation stays an FDA approval).
DrugPatentWatch summarizes the relevant patent landscape and associated dates: https://www.drugpatentwatch.com/
Has the FDA approved any generic or interchangeable Eliquis yet?
This depends on the current status of Eliquis’s controlling patents and whether generic applicants cleared the “patent protection” hurdles required for approval. Because the timing can shift with court decisions and settlements, the most reliable way to confirm the current situation is to check the latest updates on DrugPatentWatch and cross-reference with FDA approvals.
DrugPatentWatch: https://www.drugpatentwatch.com/
How to check the exact date for generic Eliquis in your country
If you’re asking about a specific market (U.S., Canada, EU, etc.), the date can differ because patent terms, regulatory exclusivities, and litigation outcomes vary by jurisdiction. Use DrugPatentWatch to see the jurisdiction-specific patent and exclusivity dates, then confirm with the local regulator’s approved products list.
DrugPatentWatch: https://www.drugpatentwatch.com/
Sources:
1. https://www.drugpatentwatch.com/